Human Longevity, Inc. has announced a strategic partnership with Alamar Biosciences, Inc. to incorporate advanced proteomic testing into its precision health offerings. This collaboration introduces two of Alamar’s NULISAseq™ multiplexed panels: the Inflammation Panel 250 and the CNS Disease Panel 120. The Inflammation Panel 250 is designed to detect and monitor chronic inflammation, a key factor in aging and age-related diseases. The CNS Disease Panel 120 focuses on early detection and monitoring of biomarkers associated with neurodegenerative and neurological disorders, providing insights into brain health and resilience.
These panels will be integrated into Human Longevity’s Executive Health and 100+ Longevity precision health programs later this year, initially available to HLI members. By leveraging Alamar’s ultra-high sensitivity proteomics platform, NULISA™, and Human Longevity’s extensive experience in integrating genomics, imaging, and multi-omics data from over 10,000 clients, clinicians and researchers will gain access to powerful new tools to measure biological processes that directly impact healthspan and lifespan.
This initiative underscores the commitment of both companies to advance longevity science through AI, multi-omics, and next-generation diagnostics.
Human Longevity, Inc., founded in 2013, is a biotechnology company at the forefront of integrating genomics, AI, and multimodal diagnostics to extend human healthspan. Alamar Biosciences, Inc. is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease.
